J Am Acad Child Adolesc Psychiatry. 2022 Nov;61(11):1317-1318. doi: 10.1016/j.jaac.2022.06.002. Epub 2022 Jun 10.
To address the issues with the current nomenclature of psychotropic agents, which may be misleading or confusing, the Neuroscience-based Nomenclature (NbN) started being developed in 2009. It was introduced as one approach to the classification of pharmacological treatments based on a medication's putative psychopharmacological mechanisms of action derived from preclinical and clinical studies. In 2018, the NbN-Child & Adolescent (NbN C&A) was released. Since then, the NbN C&A has been refined, and its website and app (https://nbnca.com/) have been implemented. JAACAP encourages its authors and readers to consider utilizing the NbN C&A and to keep abreast of its developments over time. This is in line with the core missions of the Journal: to contribute to the translation and implementation of the most up-to-date science into real-world clinical practice. DIVERSITY & INCLUSION STATEMENT: One or more of the authors of this paper self-identifies as a member of one or more historically underrepresented racial and/or ethnic groups in science.
为了解决当前精神药物命名可能存在误导或混淆的问题，基于神经科学的命名（NbN）于 2009 年开始开发。它被引入作为一种基于药物假定的精神药理学作用机制对药理学治疗进行分类的方法，这些机制源自临床前和临床研究。2018 年，发布了基于神经科学的命名-儿童和青少年版（NbN C&A）。此后，对 NbN C&A 进行了改进，并实施了其网站和应用程序（https://nbnca.com/）。JAACAP 鼓励其作者和读者考虑使用 NbN C&A，并随时了解其随时间的发展。这符合该杂志的核心使命：为将最新科学转化为现实世界的临床实践做出贡献。多样性和包容性声明：本文的一位或多位作者自认为是科学领域中一个或多个历史上代表性不足的种族和/或族裔群体的成员。
